BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 11410521)

  • 1. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells.
    Benini S; Manara MC; Baldini N; Cerisano V; Massimo Serra ; Mercuri M; Lollini PL; Nanni P; Picci P; Scotlandi K
    Clin Cancer Res; 2001 Jun; 7(6):1790-7. PubMed ID: 11410521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice.
    Scotlandi K; Benini S; Nanni P; Lollini PL; Nicoletti G; Landuzzi L; Serra M; Manara MC; Picci P; Baldini N
    Cancer Res; 1998 Sep; 58(18):4127-31. PubMed ID: 9751624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target.
    Scotlandi K; Benini S; Sarti M; Serra M; Lollini PL; Maurici D; Picci P; Manara MC; Baldini N
    Cancer Res; 1996 Oct; 56(20):4570-4. PubMed ID: 8840962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.
    Scotlandi K; Manara MC; Nicoletti G; Lollini PL; Lukas S; Benini S; Croci S; Perdichizzi S; Zambelli D; Serra M; García-Echeverría C; Hofmann F; Picci P
    Cancer Res; 2005 May; 65(9):3868-76. PubMed ID: 15867386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of IGF-I/IGF-IR circuit on the angiogenetic properties of Ewing's sarcoma cells.
    Strammiello R; Benini S; Manara MC; Perdichizzi S; Serra M; Spisni E; Picci P; Scotlandi K
    Horm Metab Res; 2003; 35(11-12):675-84. PubMed ID: 14710346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma.
    Manara MC; Landuzzi L; Nanni P; Nicoletti G; Zambelli D; Lollini PL; Nanni C; Hofmann F; García-Echeverría C; Picci P; Scotlandi K
    Clin Cancer Res; 2007 Feb; 13(4):1322-30. PubMed ID: 17317844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions.
    Scotlandi K; Manara MC; Strammiello R; Landuzzi L; Benini S; Perdichizzi S; Serra M; Astolfi A; Nicoletti G; Lollini PL; Bertoni F; Nanni P; Picci P
    J Clin Oncol; 2003 May; 21(10):1952-60. PubMed ID: 12743148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro antiproliferative effects of albumin-doxorubicin conjugates against Ewing's sarcoma and peripheral neuroectodermal tumor cells.
    Gabor F; Wollmann K; Theyer G; Haberl I; Hamilton G
    Anticancer Res; 1994; 14(5A):1943-50. PubMed ID: 7847832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing's sarcoma cells: therapeutic implications.
    Girnita L; Wang M; Xie Y; Nilsson G; Dricu A; Wejde J; Larsson O
    Anticancer Drug Des; 2000 Feb; 15(1):67-72. PubMed ID: 10888037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.
    Beltran PJ; Chung YA; Moody G; Mitchell P; Cajulis E; Vonderfecht S; Kendall R; Radinsky R; Calzone FJ
    J Pharmacol Exp Ther; 2011 Jun; 337(3):644-54. PubMed ID: 21385891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study.
    Martins AS; Ordoñez JL; García-Sánchez A; Herrero D; Sevillano V; Osuna D; Mackintosh C; Caballero G; Otero AP; Poremba C; Madoz-Gúrpide J; de Alava E
    Cancer Res; 2008 Aug; 68(15):6260-70. PubMed ID: 18676850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
    Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of cell death by basic fibroblast growth factor in Ewing's sarcoma.
    Sturla LM; Westwood G; Selby PJ; Lewis IJ; Burchill SA
    Cancer Res; 2000 Nov; 60(21):6160-70. PubMed ID: 11085540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxorubicin modulates telomerase activity in Ewing's sarcoma in vitro and in vivo.
    Lanvers-Kaminsky C; Winter B; Koling S; Frodermann B; Braun Y; Schaefer KL; Diallo R; Koenemann S; Wai D; Willich N; Poremba C; Schuck A
    Oncol Rep; 2005 Sep; 14(3):751-8. PubMed ID: 16077987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects.
    Benini S; Manara MC; Cerisano V; Perdichizzi S; Strammiello R; Serra M; Picci P; Scotlandi K
    Int J Cancer; 2004 Jan; 108(3):358-66. PubMed ID: 14648701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NVP-BEZ235 as a new therapeutic option for sarcomas.
    Manara MC; Nicoletti G; Zambelli D; Ventura S; Guerzoni C; Landuzzi L; Lollini PL; Maira SM; García-Echeverría C; Mercuri M; Picci P; Scotlandi K
    Clin Cancer Res; 2010 Jan; 16(2):530-40. PubMed ID: 20068094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
    Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
    Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling.
    Garofalo C; Manara MC; Nicoletti G; Marino MT; Lollini PL; Astolfi A; Pandini G; López-Guerrero JA; Schaefer KL; Belfiore A; Picci P; Scotlandi K
    Oncogene; 2011 Jun; 30(24):2730-40. PubMed ID: 21278796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2.
    Kalebic T; Tsokos M; Helman LJ
    Cancer Res; 1994 Nov; 54(21):5531-4. PubMed ID: 7923191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of insulin-like growth factor-I receptor with a monoclonal antibody inhibits growth of hepatic metastases from human colon carcinoma in mice.
    Bauer TW; Fan F; Liu W; Camp ER; Yang A; Somcio RJ; Bucana CD; Singh R; Ellis LM
    Ann Surg Oncol; 2007 Oct; 14(10):2838-46. PubMed ID: 17653802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.